18F-Raltegravir
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HIV-1-infection
Conditions
HIV-1-infection
Trial Timeline
Apr 1, 2018 → Jan 1, 2025
NCT ID
NCT03174977About 18F-Raltegravir
18F-Raltegravir is a phase 1 stage product being developed by Merck for HIV-1-infection. The current trial status is recruiting. This product is registered under clinical trial identifier NCT03174977. Target conditions include HIV-1-infection.
What happened to similar drugs?
12 of 19 similar drugs in HIV-1-infection were approved
Approved (12) Terminated (3) Active (6)
Hype Score Breakdown
Clinical
6
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03174977 | Phase 1 | Recruiting |
Competing Products
20 competing products in HIV-1-infection